Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol. 2023;84:191–206.

Article  PubMed  Google Scholar 

Gleave M, Goldenberg SL, Bruchovsky N, Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Prostate Cancer Prostatic Dis. 1998;1:289–96.

Article  CAS  PubMed  Google Scholar 

Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095–101.

Article  CAS  PubMed  Google Scholar 

Crawford ED, Moul JW, Sartor O, Shore ND. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin Drug Metab Toxicol. 2015;11:1465–74.

Article  CAS  PubMed  Google Scholar 

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

Article  PubMed  PubMed Central  Google Scholar 

Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Morris MJ, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer. 2012;118:3397–406.

Article  CAS  PubMed  Google Scholar 

Klil-Drori AJ, Yin H, Tagalakis V, Aprikian A, Azoulay L. Androgen deprivation therapy for prostate cancer and the risk of venous thromboembolism. Eur Urol. 2016;70:56–61.

Article  CAS  PubMed  Google Scholar 

Guo Z, Huang Y, Gong L, Gan S, Chan FL, Gu C, et al. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018;21:451–60.

Article  CAS  PubMed  Google Scholar 

Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–1500.

Article  CAS  PubMed  Google Scholar 

Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol. 2011;60:1244–50.

Article  CAS  PubMed  Google Scholar 

Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5:692–9.

Article  CAS  PubMed  Google Scholar 

Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol. 2005;16:696–701.

Article  CAS  PubMed  Google Scholar 

O’Farrell S, Sandstrom K, Garmo H, Stattin P, Holmberg L, Adolfsson J, et al. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU Int. 2016;118:391–8.

Article  PubMed  Google Scholar 

Svartberg J, Braekkan SK, Laughlin GA, Hansen JB. Endogenous sex hormone levels in men are not associated with risk of venous thromboembolism: the Tromso study. Eur J Endocrinol. 2009;160:833–8.

Article  CAS  PubMed  Google Scholar 

Brodin E, Vikan T, Hansen JB, Svartberg J. Testosterone, hemostasis, and cardiovascular diseases in men. Semin Thromb Hemost. 2011;37:87–94.

Article  CAS  PubMed  Google Scholar 

Ferenchick GS, Hirokawa S, Mammen EF, Schwartz KA. Anabolic-androgenic steroid abuse in weight lifters: evidence for activation of the hemostatic system. Am J Hematol. 1995;49:282–8.

Article  CAS  PubMed  Google Scholar 

Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers. 2018;10:380.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okwuosa TM, Morgans A, Rhee JW, Reding KW, Maliski S, Plana JC, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2021;14:e000082.

Article  CAS  PubMed  Google Scholar 

Dvorak HF, Van DeWater L, Bitzer AM, Dvorak AM, Anderson D, Harvey VS, et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res. 1983;43:4434–42.

CAS  PubMed  Google Scholar 

Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost. 2004;2:2065–7.

Article  CAS  PubMed  Google Scholar 

Stark K, Schubert I, Joshi U, Kilani B, Hoseinpour P, Thakur M, et al. Distinct pathogenesis of pancreatic cancer microvesicle-associated venous thrombosis identifies new antithrombotic targets in vivo. Arterioscler Thromb Vasc Biol. 2018;38:772–86.

Article  CAS  PubMed  Google Scholar 

Al Saleh HA, Haas-Neill S, Al-Hashimi A, Kapoor A, Shayegan B, Austin RC, et al. Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells. Prostate. 2018;78:953–61.

Article  CAS  PubMed  Google Scholar 

Chaudhry R, Usama SM, Babiker HM. Physiology, Coagulation Pathways. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

Kobayashi S, Koizume S, Takahashi T, Ueno M, Oishi R, Nagashima S, et al. Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Cancer Sci. 2021;112:4679–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105:1734–41.

Article  CAS  PubMed  Google Scholar 

Ahamed J, Versteeg HH, Kerver M, Chen VM, Mueller BM, Hogg PJ, et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci USA. 2006;103:13932–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rao LV, Pendurthi UR. Regulation of tissue factor coagulant activity on cell surfaces. J Thromb Haemost. 2012;10:2242–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reinhardt C, von Bruhl ML, Manukyan D, Grahl L, Lorenz M, Altmann B, et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Investig. 2008;118:1110–22.

CAS  PubMed  PubMed Central  Google Scholar 

Chen F, Zhao Z, Zhou J, Lu Y, Essex DW, Wu Y. Protein disulfide isomerase enhances tissue factor-dependent thrombin generation. Biochem Biophys Res Commun. 2018;501:172–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferrari DM, Soling HD. The protein disulphide-isomerase family: unravelling a string of folds. Biochem J. 1999;339:1–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Langer F, Spath B, Fischer C, Stolz M, Ayuk FA, Kroger N, et al. Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase. Blood. 2013;121:2324–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A, Puligandla M, et al. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019;4:e125851.

Article  PubMed  PubMed Central  Google Scholar 

Payne H, Brill A. Stenosis of the inferior vena cava: a murine model of deep vein thrombosis. J Vis Exp. 2017.

Araujo TLS, Zeidler JD, Oliveira PVS, Dias MH, Armelin HA, Laurindo FRM. Protein disulfide isomerase externalization in endothelial cells follows classical and unconventional routes. Free Radic Biol Med. 2017;103:199–208.

Article  CAS  PubMed  Google Scholar 

Zhou J, Wu Y, Wang L, Rauova L, Hayes VM, Poncz M, et al. The C-terminal CGHC motif of protein disulfide isomerase supports thrombosis. J Clin Investig. 2015;125:4391–406.

Article  PubMed  PubMed Central  Google Scholar 

Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008;111:190–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rothmeier AS, Liu E, Chakrabarty S, Disse J, Mueller BM, Ostergaard H, et al. Identification of the integrin-binding site on coagulation factor VIIa required for proangiogenic PAR2 signaling. Blood. 2018;131:674–85.

Article  CAS